Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

Sattar, Naveed

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. [electronic resource] - Diabetologia 10 2018 - 2155-2163 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1432-0428

10.1007/s00125-018-4702-3 doi


Adipose Tissue--metabolism
Asian People
Aspartate Aminotransferases--metabolism
Benzhydryl Compounds--therapeutic use
Diabetes Mellitus, Type 2--drug therapy
Female
Glucosides--therapeutic use
Humans
Hypoglycemic Agents--therapeutic use
Liver--drug effects
Male
Non-alcoholic Fatty Liver Disease--metabolism
Research Design
Sodium-Glucose Transporter 2--metabolism
Sodium-Glucose Transporter 2 Inhibitors--therapeutic use
Sulfonylurea Compounds--therapeutic use
Time Factors
Transaminases--metabolism
Treatment Outcome